A
Message from David Seldin, MD, PhD
Director
of the Molecular Medicine Program
and
Joseph
Loscalzo, MD, PhD
Associate
Director of the Molecular Medicine Program
To the
Prospective Student:
The
Program in Molecular Medicine is an exciting interdepartmental program
in the Division of Graduate Medical Sciences at Boston University School
of Medicine. The Molecular Medicine Program was begun by researchers
in the Department of Medicine and School of Medicine desiring to develop
a curriculum that integrates the latest advances in molecular and cellular
biology with an in-depth understanding of the molecular basis of human
disease pathophysiology. The Program is designed to build upon an understanding
of molecular pathophysiology to include relevant topics in genetic epidemiology,
clinical trial design, drug development, and health services studies.
The goal of the Program is to train PhDand MD, PhD scientists who will
have the tools to understand human disease pathogenesis and develop
innovative molecular therapeutics in the academic and biotechnological
research environments.
The faculty
of the Program in Molecular Medicine include basic scientists in the
Department of Medicine and affiliated faculty from other basic science
departments. The close integration of the Division of Graduate Medical
Sciences; the Schools of Medicine, Dental Medicine, and Public Health;
and of the clinical research departments of the Medical Center has facilitated
the development of this new program.
The program
itself involves graduate training in basic cell and molecular biology
and biochemistry, followed by a set of unique Molecular Medicine course
offerings at the advanced graduate level in Cancer Biology, Immunity
and Infection, Genetics & Epidemiology of Human Disease, and Organ
System Diseases. In the spring, a single course, "Molecules To
Molecular Therapeutics" will take a "case study" approach
to studying the entire process from understanding the epidemiology,
genetics, and molecular pathogenesis of a disease to developing innovative
therapeutics that might include bone marrow transplantation, gene therapy,
and approaches to rational drug design.
In addition,
regulatory and ethical issues in translational research will be addressed.
Sickle cell anemia will provide the first "case study" in
the upcoming academic year.
Application
to the Graduate Program in Molecular Medicine follows the procedures
of the Division of Graduate Medical Sciences. Further information can
be obtained from the website at http://www.bumc.bu.edu,
go to School of Medicine, Department of Medicine, Graduate Program in
Molecular Medicine or from the Peterson's Guide to Graduate Studies.
For further information, please contact us directly at gpmm@bmc.org.
Good luck
and hope to see you in the fall.
Sincerely,
David
Seldin, MD, PhD
Director
Joseph
Loscalzo, MD, PhD
Associate
Director
